Janssen Announces U.S. FDA Approval Of TREMFYA™ (Guselkumab) For The Treatment Of Moderate To Severe Plaque Psoriasis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/21/2026

1. SPY
2. XENE
3. NUE
4. HUBS
5. ONON
6. FFAI
7. BA
8. RTB
9. ACN
10. AAPL

Go back to Janssen Announces U.S. FDA Approval Of TREMFYA™ (Guselkumab) For The Treatment Of Moderate To Severe Plaque Psoriasis
Johnson & Johnson (NYSE: JNJ) Delayed: 269.99 --0 (-0%)
Previous Close $269.99    52 Week High $126.07 
Open $269.99    52 Week Low $94.28 
Day High $269.99    P/E 56.13 
Day Low $269.99    EPS $4.81 
Volume 3,856